Characteristics of 5115 patients enrolled in the nationwide Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project, which currently can be linked to the Danish Diabetes Database for Adults
| Variables | Patients with type 2 diabetes |
| N (%) of DD2 participants who could be linked to the Danish Diabetes Database for Adults, as of September 2015. | 5115 (73) |
| Tobacco smoking, n (%) | |
| Never smoker | 2254 (44) |
| Former smoker | 1649 (32) |
| Current smoker, daily | 886 (17) |
| Current smoker, occasionally | 55 (1) |
| Smoking status listed as unknown | 271 (5) |
| Men (n=2984) | |
| Median height (IQR), cm | 178 (174–183) |
| Height missing, n (%) | 709 (24) |
| Current median weight (IQR), kg | 96 (85–110) |
| Weight missing, n (%) | 229 (8) |
| Current BMI, n (% of those with known BMI) | |
| <18.5 | 2 (0) |
| 18.5–24.9 | 250 (11) |
| 25–29.9 | 833 (37) |
| 30+ | 1183 (52) |
| BMI missing | 716 |
| Women (n=2131) | |
| Median height (IQR), cm | 164 (160–169) |
| Height missing, n (%) | 561 (26) |
| Current median weight (IQR), kg | 84 (71–96) |
| Weight missing, n (%) | 188 (4) |
| Current BMI, n (% of those with known BMI) | |
| <18.5 | 8 (1) |
| 18.5–24.9 | 240 (15) |
| 25–29.9 | 458 (29) |
| 30+ | 861 (55) |
| BMI missing | 564 |
| HbA1c value | |
| <7% | 3592 (70) |
| 7.0%–8.0% | 824 (16) |
| 8.0%–9.0% | 303 (6) |
| ≥9.0% | 313 (6) |
| HbA1c missing | 83 (2) |
| Albuminuria, N (%) | |
| Albumin–creatinine ratio <30 mg/g | 3565 (70) |
| Albumin–creatinine ratio 30–300 mg/g | 830 (16) |
| Albumin–creatinine ratio ≥300 mg/g | 110 (2) |
| Albuminuria–creatinine ratio missing | 610 (12) |
| Blood pressure, median (IQR), mm Hg | |
| Systolic | 130 (124–140) |
| Diastolic | 80 (74–85) |
| Lipids, median (IQR), mmol/L | |
| Total cholesterol | 4.4 (3.7–5.1) |
| HDL cholesterol | 1.2 (1.0–1.5) |
| LDL cholesterol | 2.2 (1.7–2.8) |
| Triglycerides | 1.6 (1.2–2.4) |
| Physician-reported antidiabetic treatment, n (%)* | |
| Insulin only | 59 (1) |
| Insulin and oral antidiabetic treatment | 306 (6) |
| Oral antidiabetic treatment | 3993 (78) |
| None | 757 (15) |
| Physician-reported antihypertensive treatment, n (%) | 3523 (69) |
| Physician-reported ACE inhibitor or ATII-antagonist treatment, n (%) | 2786 (54) |
| Physician-reported hypolipidaemic treatment | 3373 (66) |
| Eye screening completed | 2762 (54) |
| Foot examination completed | 4362 (85) |
*Within the year prior to enrolment in the DD2 cohort.
ATII-antagonist, angiotensin 2 antagonist; BMI, body mass index; HbA1c, glycosylated haemoglobin A; HDL, high-density lipoprotein; LDL, low-density lipoprotein.